Angina
|
When Wobenzym® was added to the treatment of
angina pectoris
(chest pain due to heart problems), the frequency and
intensity of angina attacks were reduced and tolerance to
physical load was increased. A drop in pro-inflammatory
cytokine levels was also noted. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: CARVIOVASCULAR AND LYMPHATIC SYSTEMS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Angina Pectoris
Systemic enzyme therapy in the complex treatment of angina pectoris.
Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F. Systemic
enzyme therapy in the complex treatment of angina pectoris. Int. J.
Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120
- ISSN 0255-9625 218 K/375 (19-05-3)
Summary:
Complex treatment of stable angina pectoris (b-adrenoblockers,
calcium antagonists, aspirin, nitrates) with systemic enzyme therapy
positively affected the clinical course of the disease. The
frequency and intensity of angina pectoris attacks were reduced and
tolerance to physical load was increased. Dynamic echocardiography
revealed improved diastolic heart function.
Echodensitometric study of the myocardium in diastole showed
disappearance of earlier diagnosed areas of increased ultrasonic
density. The antiinflammatory, fibrinolytic and immunoregulatory
effects of systemic enzyme therapy are the main mechanisms
responsible for its beneficial effects.
Wobenzym® administration led to the reduction of
interleukin(IL)-1b and IL-8 cytokine levels.
Tumor necrosis factor-a levels tended to decrease. The phagocyte
concentration in monocytes and neutrophils and the nitroblue
tetrazolium (NBT)-test parameters substantially increased. The
effect of systemic enzyme therapy on coagulation, fibrinolysis and
the rheological properties of blood was evaluated, revealing an
increase in activated partial thromboplastin time index from 0.85 ±
0.04 to 0.97 ± 0.02 (p<0.05), plasma fibrinolytic activity and a
decrease in active platelets. In conclusion, administration of
systemic enzyme therapy in patients with angina pectoris is
pathogenetically justified and should be used in the complex
treatment of coronary heart disease.